최한곤
2018-02-22T00:29:15Z
2018-02-22T00:29:15Z
2015-09
JOURNAL OF CONTROLLED RELEASE, V. 214, Page. 30-39
0168-3659
1873-4995
https://www.sciencedirect.com/science/article/pii/S0168365915300262
http://hdl.handle.net/20.500.11754/39286
The key to making a practicable hydrogel for pharmaceutical or medical purposes is to endow it with relevant properties, i.e., facile fabrication, gelation time-controllability, and in situ injectability given a firm basis for safety/biocompatibility. Here, the authors describe an in situ gelling, injectable, albumin-cross-linked polyethylene glycol (PEG) hydrogel that was produced using a thiol-maleimide reaction. This hydrogel consists of two biocompatible components, namely, thiolated human serum albumin and 4-arm PEG(20k)-maleimide, and can be easily fabricated and gelled in situ within 60 s by simply mixing its two components. In addition, the gelation time of this system is controllable in the range 15 s to 5 min. This hydrogel hardly interacted with an apoptotic TRAIL protein, ensuring suitable release profiles that maximize therapeutic efficacy. Specifically, tumors (volume: 278.8 mm(3)) in Mia Paca-2 cell-xenografted BALB/c nu/nu mice treated with the TRAIL-loaded HSA-PEG hydrogel were markedly smaller than mice treated with the hydrogel prepared via an amine-N-hydroxysuccinimide reaction or non-treated mice (1275.5 mm(3) and 1816.5 mm(3), respectively). We believe that this hydrogel would be a new prototype of locally injectable sustained-release type anti-cancer agents, and furthermore offers practical convenience for a doctor and universal applicability for a variety of therapeutic proteins. (C) 2015 Elsevier B.V. All rights reserved.
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (#2014002133).
en_US
ELSEVIER SCIENCE BV
Hydrogel
Polyethylene glycol
Albumin
In situ formation
TNF-related apoptosis-inducing ligand
Pancreatic cancer
HUMAN SERUM-ALBUMIN
LIGAND TRAIL
CRYSTAL-STRUCTURE
MOUSE SKIN
DELIVERY
RELEASE
DRUG
PEGYLATION
CHITOSAN
CARRIER
In situ facile-forming PEG cross-linked albumin hydrogels loaded with an apoptotic TRAIL protein
Article
10.1016/j.jconrel.2015.07.012
30-39
JOURNAL OF CONTROLLED RELEASE
Kim, IS
Choi, JS
Lee, S.H
Byeon, HJ
Lee, ES
Shin, BS
Choi, HG
Lee, KC
Youn, YS
2015002880
E
COLLEGE OF PHARMACY[E]
DEPARTMENT OF PHARMACY
hangon